Long-term safety of admilparant in people with pulmonary fibrosis
Checks long-term safety of admilparant in people who finished earlier pulmonary fibrosis studies.
Plain-language title generated from the registry record
Registry title: Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Key facts
- Where
- Berlin, Coswig, Freiburg im Breisgau, Hamburg, Immenhausen, Mainz, Munich, and Stralsund, GermanySee the 9 sites
- Phase
- Phase 3
Where in Germany
- Helios Klinikum Emil von Behring GmbHBerlin, GermanyNot yet recruiting
- Vivantes Netzwerk fuer Gesundheit GmbHBerlin, GermanyNot yet recruiting
- Fachkrankenhaus Coswig GmbHCoswig, GermanyNot yet recruiting
- Medical Center- University of FreiburgFreiburg im Breisgau, GermanyNot yet recruiting
- University Medical Center Hamburg-EppendorfHamburg, GermanyNot yet recruiting
- Lungenfachklinik ImmenhausenImmenhausen, GermanyNot yet recruiting
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyNot yet recruiting
- LMU Klinikum Muenchen AöRMunich, GermanyNot yet recruiting
- HELIOS Hanseklinikum Stralsund GmbHStralsund, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07441408EU 2025-522373-10-00
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).Read full original descriptionShow less
An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
Inclusion: Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015.
Exclusion: Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation; Exhibit symptoms of heart failure at rest; History of lung reduction surgery or lung transplant; Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy; Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015; Other protocol-defined Inclusion/Exclusion criteria apply.